Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) shares surged after the U.S. Food and Drug Administration approved BYSANTI™ (milsaperidone), a new treatment for adults with bipolar I…
Moderna, Inc. (NASDAQ: MRNA) tumbled sharply this week after the U.S. Food and Drug Administration (FDA) announced it would not review the company’s application for…
Citius Oncology (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (NASDAQ: CTXR), has signed an exclusive European Union distribution agreement for its oncology immunotherapy LYMPHIR™…
Merck & Co. (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX for the treatment of certain…
Novo Nordisk (NYSE: NVO) reported new late-stage clinical results showing its next-generation obesity therapy CagriSema outperformed Wegovy in a head-to-head study, strengthening the company’s position…
February 09, 2026
OraGenics Targets $9B Concussion Market With Clinical-Stage Intranasal Therapy ONP-002
OraGenics, Inc. (NYSE American: OGEN) outlined its 2026 clinical and operational roadmap as it advances ONP-002, an intranasal neurosteroid candidate positioned as a potential first-in-class…
February 06, 2026
Novo Nordisk Shares Rebound After FDA Signals Continued Support for GLP-1 Approvals
Novo Nordisk (NYSE: NVO) shares recovered Thursday following remarks from the U.S. Food and Drug Administration that reiterated support for ongoing and upcoming obesity and…
February 04, 2026
Eli Lilly Raises Outlook as Obesity Drugs Power Strong Q4 Results
Eli Lilly and Company (NYSE: LLY) delivered a strong fourth-quarter performance and issued upbeat guidance, driven by continued momentum in its fast-growing obesity and diabetes…
February 03, 2026
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics, Expanding Rare-Disease Pipeline
Cycle Pharmaceuticals has completed its acquisition of Applied Therapeutics (NASDAQ: APLD), strengthening Cycle’s position in rare metabolic and neurological diseases. The transaction, funded with cash…
January 30, 2026
FDA Approves First Combination Eye Drop for Presbyopia, Opening a New Vision-Care Market
The U.S. Food and Drug Administration has approved Yuvezzi, the first combination eye-drop therapy for presbyopia, the age-related condition that causes blurry near vision and…
January 30, 2026
MediciNova Reaches 100-Patient Milestone in Expanded Access Program for ALS Treatment
MediciNova (NASDAQ: MNOV) announced that 100 patients with amyotrophic lateral sclerosis (ALS) have now been enrolled in its SEANOBI Expanded Access Program (EAP) evaluating MN-166…
OKYO Pharma (NASDAQ: OKYO) reported a successful Type C meeting with the U.S. Food and Drug Administration, marking an important regulatory milestone for its lead…